Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/11821

Authors: Fontaine, C.
Dopchie, C.
Nouwynck, C.
Issue Date: 2010
Citation: ANNALS OF ONCOLOGY, 21. p. 108-108
Abstract: Introduction: Current treatment recommendations for MBC provide limited guidance for chemotherapy (CT), whereas physicians have many options to choose from, including potentially cardiotoxic agents. We undertook a retrospective survey to describe actual CT approaches to MBC in clinical practice in Belgium. Methods: Data were collected for metastatic patients diagnosed in 2003-2009 and treated with ‡1 CT regimen for MBC. Two academic centers and 18 general hospitals participated in the survey. Demographic, disease and treatment data of the last 25 consecutively treated pts per hospital were collected and analyzed. Prevalence of cardiovascular (CV) risk factors was determined as well. Results: 490 pts (mean age 59 yrs) were included. 44% had at least one CV risk factor at the time of MBC diagnosis, including hypertension (21%), hypercholesterolemia (17%), smoking (10%), and/or diabetes (7%) Percentages of pts receiving 1, 2, 3, 4, 5, and ‡6 lines of CT were 100, 79, 55, 30, 18, and 9%, respectively. Combination CT was given to 54% in line 1, 33% in line 2, and 35% in line 3. In line 1, taxane monotherapy (46%), FEC (40%), and taxane-trastuzumab combinations (19%) were the predominant regimens. Many different CT regimens were used throughout all lines, e.g. >20 regimens in line 1. Most pts had received a taxane (94%) or an anthracycline (60%), either as monotherapy or in combination CT, mostly in line 1 or 2. Elderly pts (‡70 yrs) received fewer consecutive lines of CT (32 vs. 61% received ‡3 lines), less combination CT (39 vs. 58% in line 1) and less toxic agents than younger pts. Date of the MBC diagnosis before or after Jan. 1, 2006 had no major effect on the type of CT given, although there was a tendency to a larger diversity of CT regimens in the later cohort. Conclusions: A wide diversity of monotherapy and combination CT regimens is used to treat MBC in Belgium throughout all lines of treatment. Nevertheless, taxanes and anthracyclines are the cornerstones of CT for MBC. Elderly pts are treated less intensively and with fewer regimens than younger pts. CV risk factors appeared to be highly prevalent in the survey population. This should be taken into account in the choice of CT for MBC and pt management.
Notes: [Fontaine, C.] UZ Brussel, Brussels, Belgium. [Janssens, J.] Univ Hasselt, Hasselt, Belgium. [Nouwynck, C.] Free Univ Brussels, Erasme Hosp, B-1050 Brussels, Belgium. [Dopchie, C.] Clin Notre Dame, Tournai, Belgium.
URI: http://hdl.handle.net/1942/11821
ISI #: 000283115900331
ISSN: 0923-7534
Category: M
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.